SUMMARY
Leishmania braziliensis infection results in inflammation and skin injury, with highly variable and unpredictable clinical outcomes. Here, we investigated the potential impact of microbiota on infection-induced inflammatory responses and disease resolution by conducting an integrated analysis of the skin microbiome and host transcriptome on a cohort of 62 L. braziliensis-infected patients. We found that overall bacterial burden and microbiome configurations dominated with Staphylococcus spp. were associated with delayed healing and enhanced inflammatory responses, especially by IL-1 family members. Dual RNA-seq of human lesions revealed that high lesional S. aureus transcript abundance was associated with delayed healing and increased expression of IL-1β. This cytokine was critical for modulating disease outcome in L. braziliensis-infected mice colonized with S. aureus, as its neutralization reduced pathology and inflammation. These results implicate the microbiome in cutaneous leishmaniasis disease outcomes in humans and suggest host-directed therapies to mitigate the inflammatory consequences.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the following grants from the NIH (R01AI143790 to PS/EAG, R01NR015639 to EAG, and P50 AI030639 to E.M.C.). This research was also supported by the Penn Skin Biology and Disease Resource-based Center (Penn SBDRC supported by NIH/NIAMS P30AR069589). VML is supported by NIAMS F31AR079901 and JCH was supported by NIAMS F31AR079845 and the Penn Dermatology Research T32 Training Grant (NIH/NIAMS T32AR007465).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted according to the principles specified in the Declaration of Helsinki and under local ethical guidelines (Ethical Committee of the Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Bahia, Brazil, and the University of Pennsylvania Institutional Review Board).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title was updated; The data availability paragraph was updated with new URLs;
Data Availability
All data associated with this study are present in the paper or the Supplementary Materials. Raw sequence data are available at the Sequence Read Archive (SRA) as follows: bulk RNA-seq GEO BioProject PRJNA885131, 16S-seq and whole genome sequencing for S. aureus clinical isolates SRA BioProject PRJNA922957. Shell scripts and main R scripts are available in GitHub https://github.com/camilafarias112/Amorim_LeishMicrobiome. Tables from DGE analysis and GO analysis are available within this manuscript as Supplemental Tables.
